CUE - Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
Story updates
10:01:43 AM UTC
SquawkNews
Cue Biopharma reported positive topline Phase 2 results for CUE-221 in chronic spontaneous urticaria, meeting the primary endpoint across all doses and a key secondary endpoint at 4 mg/kg, with favorable safety. The company plans a Phase 2b/3 study in CSU.Material DetailsContext by AI AnalystThis i…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.